In this retrospective analysis, postoperative administration of hydroxyethyl starch 130/0.42 did not increase the risk for acute kidney injury or 90-day mortality in patients after elective coronary artery bypass grafting, aortic valve replacement, or a combination of both.

Early administration of hydroxyethyl starch 130/0.42 in a low dosage showed the potential to slow down the postoperative decline of the renal function after cardiac surgery.

When transferring and extrapolating renal safety data, patient populations and clinical settings might be of particular importance and might modulate the effects.